Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvemcitug plus trifluridine/tipiracil in refractory metastatic colorectal cancer
NCT07361003Phase 3Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Nov 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of suvemcitug in colorectal cancer (metastatic) (mCRC), sponsored by Simcere Pharmaceutical Group. Started Nov 2025; status: recruiting.
02
Drugs
suvemcitug
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT07361003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361003.